We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Q4 Earnings: These Buy-Rated Stocks Crushed Expectations
Key Takeaways
The 2025 Q4 earnings season remains one of strength.
PLTR and CAH knocked it out of the park this cycle.
Both stocks also sport a favorable buy-rated Zacks Rank.
The 2025 Q4 earnings cycle keeps rolling along, with a wide array of S&P 500 companies already delivering results. The period has yet again been one of resilience, with overall growth remaining strong.
But more specifically, this cycle, several buy-rated companies – Cardinal Health (CAH - Free Report) and Palantir (PLTR - Free Report) – posted results that were notably strong.
Palantir Growth Remains Stellar
Palantir again continued to fire on all cylinders throughout the period, with overall sales of $1.4 billion flying 70% year-over-year. U.S. results were rock-solid again, underpinned by both commercial and government strength. Specifically, U.S. sales totaled $1.1 billion, growing 93% year-over-year and an even more impressive 28% sequentially.
Further, Palantir closed more than $4.2 billion of total contract value (TCV) overall, up more than 130% from the year-ago period. And its consumer base keeps snowballing, with customer count surging 34% from the year-ago period.
Below is a chart illustrating the company’s sales on a quarterly basis.
Image Source: Zacks Investment Research
Shares have had a tough showing over recent weeks, with some profit-taking likely occurring after a massive run. While price action hasn’t been ideal, the company’s current fiscal year EPS outlook remains bullish, as shown below. The stock remains a Zacks Rank #2 (Buy).
Image Source: Zacks Investment Research
Cardinal Health Raises Guidance
Cardinal Health posted a double-beat relative to our consensus expectations, with sales soaring 18.8% from the year-ago period alongside a sizable 36.3% year-over-year growth rate in adjusted EPS.
Cardinal Health’s sales have seen great growth over recent periods after some stagnation throughout 2024, as shown in the chart below.
Image Source: Zacks Investment Research
Strength was primarily broad-based across its segments, with sales in Pharmaceuticals and Specialty Solutions climbing 19% year-over-year. Keep in mind that its Pharmaceuticals and Specialty Solutions accounts for the vast majority of its sales, contributing roughly 90%.
Cardinal Health raised its FY26 outlook following the strong quarter, now expecting adjusted EPS in a band of $10.15 - $10.35, with the midpoint suggesting 24.5% year-over-year growth. The updated outlook is reflected in positive earnings estimate revisions, as shown below. The stock sports a favorable Zacks Rank #1 (Strong Buy).
Image Source: Zacks Investment Research
Bottom Line
The 2025 Q4 earnings season continues to roll along, with the period largely positive and resilient.
And throughout the period, several buy-rated companies – Palantir (PLTR - Free Report) and Cardinal Health (CAH - Free Report) – posted very strong quarterly results.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Shutterstock
Q4 Earnings: These Buy-Rated Stocks Crushed Expectations
Key Takeaways
The 2025 Q4 earnings cycle keeps rolling along, with a wide array of S&P 500 companies already delivering results. The period has yet again been one of resilience, with overall growth remaining strong.
But more specifically, this cycle, several buy-rated companies – Cardinal Health (CAH - Free Report) and Palantir (PLTR - Free Report) – posted results that were notably strong.
Palantir Growth Remains Stellar
Palantir again continued to fire on all cylinders throughout the period, with overall sales of $1.4 billion flying 70% year-over-year. U.S. results were rock-solid again, underpinned by both commercial and government strength. Specifically, U.S. sales totaled $1.1 billion, growing 93% year-over-year and an even more impressive 28% sequentially.
Further, Palantir closed more than $4.2 billion of total contract value (TCV) overall, up more than 130% from the year-ago period. And its consumer base keeps snowballing, with customer count surging 34% from the year-ago period.
Below is a chart illustrating the company’s sales on a quarterly basis.
Image Source: Zacks Investment Research
Shares have had a tough showing over recent weeks, with some profit-taking likely occurring after a massive run. While price action hasn’t been ideal, the company’s current fiscal year EPS outlook remains bullish, as shown below. The stock remains a Zacks Rank #2 (Buy).
Image Source: Zacks Investment Research
Cardinal Health Raises Guidance
Cardinal Health posted a double-beat relative to our consensus expectations, with sales soaring 18.8% from the year-ago period alongside a sizable 36.3% year-over-year growth rate in adjusted EPS.
Cardinal Health’s sales have seen great growth over recent periods after some stagnation throughout 2024, as shown in the chart below.
Image Source: Zacks Investment Research
Strength was primarily broad-based across its segments, with sales in Pharmaceuticals and Specialty Solutions climbing 19% year-over-year. Keep in mind that its Pharmaceuticals and Specialty Solutions accounts for the vast majority of its sales, contributing roughly 90%.
Cardinal Health raised its FY26 outlook following the strong quarter, now expecting adjusted EPS in a band of $10.15 - $10.35, with the midpoint suggesting 24.5% year-over-year growth. The updated outlook is reflected in positive earnings estimate revisions, as shown below. The stock sports a favorable Zacks Rank #1 (Strong Buy).
Image Source: Zacks Investment Research
Bottom Line
The 2025 Q4 earnings season continues to roll along, with the period largely positive and resilient.
And throughout the period, several buy-rated companies – Palantir (PLTR - Free Report) and Cardinal Health (CAH - Free Report) – posted very strong quarterly results.